BPC-157

BPC stands for Body Protection Compound. It was isolated by a research group in Croatia in the 1990s. The body does not make BPC-157 on its own. It makes a much larger protein found in gastric juice, and BPC-157 is a 15-amino-acid fragment of that parent protein. Interest in gut-derived healing compounds is old: the same Pavlov known for his work with dogs also studied gastric juice as a medicine for digestive complaints. BPC-157 was first explored as a treatment for the gut, and its reputation for tendon and muscle repair came later.

BPC-157 is best known online for tendon, ligament, and muscle recovery, but a lot of the research interest sits in the gut, where it was first studied. People also read about it for general digestive comfort. There is early interest in effects on the gut-brain axis as well, including reports around cravings and mood, though that area is far less studied than its repair effects.

A few things set BPC-157 apart. It has no known receptor, so researchers think it may work by adjusting proteins the body already makes rather than by hitting a single target. It appears to promote repair rather than simply block inflammation, often described as pressing the gas pedal on the body's own healing. In one tendon model it increased the number of growth-hormone receptors on the tissue, which could help the tendon respond to growth signals. In animal studies it also supported healing even when corticosteroids, which usually slow healing, were given at the same time.

BPC-157 is taken either by injection or orally, and the difference matters more than it might seem. Taken orally, it has generally not been detectable in the bloodstream, which suggests it may act locally in the gut rather than travel through the body. Injected BPC-157 does reach the wider system. This is why oral forms are usually associated with gut goals and injectable forms with tendon or muscle goals. This is background, not a recommendation.

BPC-157 has a long research history, and its tolerability record is a standout. In animal studies no lethal dose has been found even at very high amounts, and it is widely regarded as one of the most well tolerated peptides. Most of the research is in animals, and a large share of that work traces to a single Croatian research group, with some replication by others. Formal human trials are still limited, the main example being a small set of early trials using BPC-157 for a gut condition. The honest summary is a compound with an excellent tolerability record and a deep body of animal data, alongside a small amount of formal human research.

BPC-157 has not been approved by the FDA. In late 2024 it was placed on an FDA list that restricts pharmacy compounding, alongside a number of other peptides. It is sometimes sold under the name PDA, short for pentadecapeptide arginate, which is the same compound in a different salt form. It also appears on anti-doping watch lists, so athletes in tested sports should be aware of it. Rules in this area are changing quickly, so treat any status as a snapshot in time.